- Home
- NML vs XERS Comparison
NML vs XERS Comparison
Compare NML & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- XERS
- Stock Information
- Founded
- NML 2012
- XERS 2005
- Country
- NML United States
- XERS United States
- Employees
- NML N/A
- XERS N/A
- Industry
- NML Finance/Investors Services
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- NML Finance
- XERS Health Care
- Exchange
- NML Nasdaq
- XERS Nasdaq
- Market Cap
- NML 461.2M
- XERS 444.0M
- IPO Year
- NML N/A
- XERS 2018
- Fundamental
- Price
- NML $9.28
- XERS $3.04
- Analyst Decision
- NML
- XERS Buy
- Analyst Count
- NML 0
- XERS 3
- Target Price
- NML N/A
- XERS $4.87
- AVG Volume (30 Days)
- NML 219.3K
- XERS 1.9M
- Earning Date
- NML 01-01-0001
- XERS 11-08-2024
- Dividend Yield
- NML 9.75%
- XERS N/A
- EPS Growth
- NML N/A
- XERS N/A
- EPS
- NML N/A
- XERS N/A
- Revenue
- NML N/A
- XERS $187,361,000.00
- Revenue This Year
- NML N/A
- XERS $20.35
- Revenue Next Year
- NML N/A
- XERS $16.14
- P/E Ratio
- NML N/A
- XERS N/A
- Revenue Growth
- NML N/A
- XERS 22.72
- 52 Week Low
- NML $6.09
- XERS $1.69
- 52 Week High
- NML $7.33
- XERS $3.64
- Technical
- Relative Strength Index (RSI)
- NML 77.71
- XERS 46.54
- Support Level
- NML $8.87
- XERS $2.82
- Resistance Level
- NML $9.14
- XERS $3.33
- Average True Range (ATR)
- NML 0.15
- XERS 0.19
- MACD
- NML 0.05
- XERS -0.04
- Stochastic Oscillator
- NML 94.87
- XERS 26.83
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.